

SIGNATURE PRIORITY

Institute for Cell Therapy Discovery & Innovation

Engineering immune cells to transform cancer treatment

Experts at MD Anderson Cancer Center have been instrumental in shaping the field of cell therapy by engineering groundbreaking treatments and leading clinical trials to confirm safety and efficacy.

Some cancers resist interventions available through existing treatments. The Institute for Cell Therapy Discovery & Innovation will fuel the creation of breakthrough therapies that can be readily adapted to address emerging needs.

Cell therapies are a revolutionary approach to cultivating immune cells and enhancing their targeting abilities. CAR NK cell therapy, the focus of the institute's research, has shown early success with durable remission in some blood cancers without the potential side effects of CAR T cell therapy. CAR NK cell therapy also is being tested in solid tumors and autoimmune diseases.

MD Anderson has the infrastructure and expertise required to rapidly advance this lifesaving work. Building on the momentum we have established, our goals for the future include:

- Developing off-the-shelf cell therapies for use against blood cancers, solid tumors and autoimmune diseases
- Improving potency while reducing toxicity when compared with the current standard of care
- Exploring combinations of therapies to customize treatment plans
- Lowering the cost by considering new source strategies, refining the manufacturing process and leveraging industry partnerships

MISSION

Eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public

5 THINGS TO KNOW ABOUT MD ANDERSON

- MD Anderson Cancer Center is ranked No. 1 in the nation for cancer care in U.S. News & World Report's "Best Hospitals" survey and has been named one of the nation's top two hospitals for cancer care since the survey began in 1990
- Saw 187,000 patients, completed 1.7 million outpatient visits and delivered \$346 million in uncompensated care in the past fiscal year
- Home to the world's largest cancer clinical trials program
- Invested \$1.3 billion in research in the past fiscal year
- Received 188 patents and tested 27 drugs that received Food and Drug Administration (FDA) approval in the past fiscal year

To learn more, visit MDAnderson.org/QuickFacts

